Semaglutide: kidneys, heart and weight at mypeptidesrx

Kidney outcomes in FLOW

After the kidney result, I hesitate over calling semaglutide the runner-up. FLOW studied 3,533 people with type 2 diabetes and chronic kidney disease. Its primary composite included kidney failure, a major decline in eGFR—the estimated filtration rate—and kidney- or cardiovascular-related death.

The risk was 24% lower relative to placebo (HR 0.76, 95% CI 0.66-0.88). That is a comparison of event risk in this trial population, rather than a claim that kidney function improved by 24%. Preserving function and increasing a laboratory value describe different goals.

FLOW’s population had two conditions together: type 2 diabetes and chronic kidney disease.

SELECT’s cardiovascular endpoint

SELECT asked about cardiovascular death, non-fatal myocardial infarction and non-fatal stroke in 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. The composite was reduced by a relative 20% versus placebo (HR 0.80, 95% CI 0.72-0.90, P<0.001).

I value the fact that this trial counted clinical events. A favourable weight or blood-sugar change can suggest a possible future benefit; SELECT tested an event outcome directly. Its eligibility criteria still matter. The result belongs to people with existing cardiovascular disease, and a reader without that history brings a different baseline risk.

STEP 1 and SURMOUNT-5

In STEP 1, 1,961 adults with overweight or obesity without diabetes had a mean body-weight change of -14.9% at 68 weeks with semaglutide, versus -2.4% with placebo. That remains a substantial result.

Then SURMOUNT-5 compared maximum tolerated doses of semaglutide and tirzepatide for 72 weeks in 751 adults with obesity without type 2 diabetes. Mean weight changes were -13.7% with semaglutide and -20.2% with tirzepatide (P<0.001). For that outcome in that comparison, tirzepatide performed better.

The weight result initially dominated my impression. After FLOW and SELECT, I judged the drugs by the treatment goal before drawing a larger verdict. SURMOUNT-5’s weight endpoint cannot decide a head-to-head kidney or cardiovascular claim.

Appetite, formulation and approved uses

Semaglutide mimics GLP-1, a gut hormone involved in glucose-dependent insulin release and appetite. Its modifications resist rapid breakdown and promote albumin binding, giving it a much longer working life than native GLP-1. The safety review discusses the clinical pharmacology alongside tolerability.

The approved uses covered here are type 2 diabetes, chronic weight management, cardiovascular-risk reduction in adults with established cardiovascular disease and overweight or obesity, kidney-event reduction in type 2 diabetes with chronic kidney disease, and MASH, a liver condition, since 2025. Injectable and oral formulations exist. Their administration requirements differ; this site provides no personal regimen.

Community descriptions of quieter “food noise,” reduced cravings and less interest in alcohol are anecdotal accounts, not clinical evidence. Nausea, reflux, constipation, diarrhoea, sulfur-smelling burps and early fatigue also appear in those reports. I take the language of daily experience seriously, while leaving claims about how often an effect occurs to measured data.

Safety questions that affect the goal

The 2021 safety review gives semaglutide a favourable overall risk-benefit assessment in type 2 diabetes, with gastrointestinal intolerance and increased biliary-disease risk among its cautions. It also discusses retinopathy monitoring when glucose improves rapidly. A treatment aimed at glucose control can create its own monitoring needs.

The thyroid C-cell-tumour boxed warning derives from rodent studies. Personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication; the animal finding does not establish a human cancer effect. The review describes pancreatic- and thyroid-cancer questions as unresolved because the events are rare. I distrust certainty built from a thin record of rare events.

Compare semaglutide with the other peptides, or turn to tirzepatide’s direct trial results.

The term srmaglthreon

This bibliography does not establish what “srmaglthreon” denotes. The semaglutide trials discussed here cannot identify that string as semaglutide, another peptide or a verified spelling correction.

Peptides RX LLC

This page summarises semaglutide research. Its cited sources do not establish the identity or offerings of “Peptides RX LLC”; the compound findings cannot answer those questions about the named entity.